Navigation Links
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Date:5/8/2008

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.

The objectives of the trial are: (i) to define the maximum tolerated dose (MTD) of Cloretazine(R) (VNP40101M) when given in combination with cytarabine to AML and high-risk MDS patients over the age of 60, and (ii) to evaluate this combination further for safety and efficacy in a larger cohort of patients. Cloretazine(R) (VNP40101M) will be given as a 30 - 60 minute infusion on day 1 approximately 3-4 hours after the start of the cytarabine infusion. Cytarabine will be administered as a continuous infusion of 100 mg/m2/day for 7 days. In the Phase I portion of the study, dose escalation will be done in cohorts of at least 3 patients and the maximum tolerated dose (MTD) identified in the Phase I segment will be used in the Phase II segment of the study.

Ann Cahill, Vice President, Clinical Development, commented, "It is important for us to continue to study Cloretazine(R) (VNP40101M) in combination with different doses and schedules of cytarabine, the most widely used drug in the treatment of AML. In addition, we want to evaluate Cloretazine(R) (VNP40101M) in a broader group of elderly patients than are currently being studied in our pivotal tri
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
2. Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
3. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
6. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
7. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
8. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
9. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
10. Cequent Pharmaceuticals Johannes Fruehauf, MD, Ph.D., to be Featured Speaker at RNAi World Congress in Boston - May 2, 2008
11. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...W YORK, Nov. 20 Reportlinker.com a...lable in its catalogue. ,, Blood Pressure Moni...ket Analysis ,, http://www.reportlinker.com/...struments---A-World-Market-Analysis.html#utm_sourc...newswire ,, Measurement of blood pressure is ...
(Date:11/20/2009)...W YORK, Nov. 20 Reportlinker.com a...lable in its catalogue. ,, Pipettes & Pipe...//www.reportlinker.com/p0164373/Pipettes--Pipettor...newswire&utm_medium=pr&utm_campaign=prnews... an integral part of any research laboratory. Larg...
(Date:11/20/2009)...W YORK, Nov. 20 ,, Reportlinker...s available in its catalogue. ,, Global Market...ww.reportlinker.com/p0164741/Global-Markets-for-Br...e&utm_medium=pr&utm_campaign=prnewswire ... includes the spring loaded core needle market and...
Breaking Medicine Technology:Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 2Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 3Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 4Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 5Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 6Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 7Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 8Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Kendle Names Jarrod Pontius Chief Legal Officer 12829 1Kendle Names Jarrod Pontius Chief Legal Officer 12829 2Studies Indicate Good Nutrition Linked to Eye Health 50287 1Studies Indicate Good Nutrition Linked to Eye Health 50287 2Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 1Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 2Surgeons Use USGI Medicals Incisionless Operating Platform to Reduce Pouch Stoma Size in Gastric Bypass Patients 50285 3
...emotherapy and pegylated enzyme produces signif... alone - - Pegylated enzyme well ...utics,Inc. (Nasdaq: HALO ), a biopharmaceutical c...geting the extracellular matrix, today,announced t...ficacy data,for its pegylated-rHuPH20 enzyme (PEGP...
...l,s Genetic Risk Based on Clinical Data, Preven...aterials, WALTHAM, Mass., July 22 Interleukin Ge...nch of an enhanced test report,format and informat... Test.,The test is currently marketed under the br...uixtar/Amway. The new report will include quantifi...
Other Medicine Technology:Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3
(Date:11/20/2009)... , NEW YORK, Nov. 20 /PRNewswire-FirstCall/...nced that it will broadcast Doctor Radio Report... , an in-depth special hosted by veteran journalis...om/cgi-bin/prnh/20080819/NYTU044LOGO ) ,, Doct... About Mammograms will air November 21 live at ...
(Date:11/20/2009)... durations of exposure to formaldehyde used for em...th an increased risk of death from myeloid leukemi...ber 20 in the Journal of the National Cancer Inst...tality from lymphohematopoietic malignancies and b...al industry workers, all of whom may have worked w...
(Date:11/20/2009)...ttle, Washington) November 20, 2009Emergency medic...sess an estimated 350,000 cardiac arrests each yea... cardiac arrest survive. Better quality cardiopul... EMS providers may be associated with better patie... (ROC) is the largest clinical research network to...
(Date:11/20/2009)... thinks it,s as short as 34 weeks, potentially add... , FRIDAY, Nov. 20 (HealthDay News) -- Recent r...ntinues to climb in the United States. Now, a new...fused about what constitutes a full-term birth in ...hers surveyed in the study considered a baby born ...
(Date:11/20/2009)...an study finds more severe cases than with seasona...ws) -- Canadian researchers are reporting that chi...e cases of H1N1 flu than seasonal flu. , "Asthm... for admission with pandemic H1N1 influenza, prese...es," wrote Dr. Upton Allen and fellow researchers ...
Breaking Medicine News(10 mins):Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 2Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 3Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 4Health News:SIRIUS XM to Broadcast 'Doctor Radio Reports: What Every Woman Needs To Know About Mammograms' 5Health News:Funeral industry workers exposed to formaldehyde face higher risk of leukemia 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4
...pril 23 I Lost It at the Club!, a,fitness industr...nated by,the International Health, Racquet & Sport... Foods, AllWhites(R), helped a total of 25,840,par...lub!, which ran for eight weeks from January 7 to ...
...h., April 23 Perrigo Company,(Nasdaq: PRGO ; TAS...results,for its third quarter fiscal 2008 on Tuesd...he Company will conduct a conference call at 10:00...ested,parties on the Perrigo website http://www.p...
...anted into mice, they improved heart function, res...ealthDay News) -- A multinational team of research...cells into three types of human heart muscle cells... be to use the cells to test drugs. , "We have now...
...nual Meeting, WASHINGTON, April 23 Medical devic...cials will gather for the 2008,Annual Meeting of t... on,June 12th and 13th at the Marriott at Metro Ce...l technology,companies. The Annual Meeting brings ...
... Property Expands to 41 Patents in more than 20 Co...Medical,Corporation, a medical products company de...performance through Aortic Flow Therapy, announced...,System and Method of Applying Same." The ,921 pat...
...if., April 23 Kaiser Permanente has,announced the...fornia,Member Service Call Centers. Ward previousl...ll Centers. She joined Kaiser Permanente in 1988.,...nclude more than 700 employees answering a wide va...
Other Medicine News:Health News:U.S. Health Club Members Proclaim - 'I Lost It at the Club!' and Lose 45 Tons of Excess Weight 2Health News:U.S. Health Club Members Proclaim - 'I Lost It at the Club!' and Lose 45 Tons of Excess Weight 3Health News:U.S. Health Club Members Proclaim - 'I Lost It at the Club!' and Lose 45 Tons of Excess Weight 4Health News:Embryonic Stem Cells Turned Into Three Types of Heart Cells 2Health News:Key Industry and Government Officials to Address Medical Technology Executives 2Health News:Orqis(R) Medical Awarded 15th U.S. Patent 2Health News:Trenita Ward Named Vice President, California Member Service Call Centers for Kaiser Permanente 2
.... The bodys warmth beneath drapes. The life-giving...e yours to guard, measure, stabilize and cross che...ts helps you do your job, giving you the informati...ise management of your patients stability during s...
... compact, lightweight system with streamlined ther...ng the same intensity (50 mW/cm) of its elder brot...cm). Excilite- possesses the latest in technology,...al users. The system is fitted with additional scr...
...stem with one single wavelength of 1064nm, availab...ties of either 60 W or 100 W, and it is a valid al...laser is the classical version of Smart1064 family...linics which would like to have a versatile system...
SmartLipo
Medicine Products: